The growth of Viagra and its impact on the medicinal landscape presents a intricate question for traders. While the first sales figures were remarkable, the patent has ended, leading to a deluge of copycat alternatives that are eroding earnings. Moreover, the industry is facing challenges related to aging trends and changing healthcare regulations,